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The Unknown Effect of
Clopidogrel Resistance in Dual
Antiplatelet Therapies After
Coronary Artery Bypass Grafting
We read with great interest the article of Sørensen et al. (1) that
reported the efficacy of post-operative clopidogrel treatment in a
large patient cohort revascularized with coronary artery bypass
graft surgery (CABG) after myocardial infarction. Notwithstand-
ing the criterion of preoperative myocardial infarction, it remains
interesting that this result is contrary to the CASCADE (Clopi-
dogrel After Surgery for Coronary Artery DiseasE) trial, where
addition of clopidogrel to aspirin revealed no changes on the
post-operative outcomes (survival, 1-year intimal hyperplasia) (2).
A possible explanation could be the different rates of aspirin and/or
clopidogrel resistance between the 2 populations.
Aspirin resistance after cardiac surgery varies between 7% and
54% (depending on the platelet assay) (3). In contrast, clopidogrel
response in patients undergoing CABG remains unknown due to
the fact that aspirin is the drug of first choice after CABG, and
clopidogrel administration (in addition to aspirin) is recommended
mainly in patients with acute coronary syndrome (1). However,
previous reports indicate that the clopidogrel resistance rate in
coronary stent patients varies between 5% and 56% (4). Besides,
carriers of defective alleles for CYP2C19 and CYP2C9 and patients
undergoing omeprazole and atorvastatin therapy (inhibitors ofCYP2C19 and CYP3A4, respectively) are at risk of clopidogrel
resistance as well (5).
Certainly, the considerably high prevalence of clopidogrel resis-
tance in noncardiac surgery patients creates the necessity for
assessment of clopidogrel nonresponders undergoing CABG.
Otherwise, it remains unknown in dual antiplatelet therapies
whether the response to clopidogrel covers a possible aspirin
resistance or vice versa. Finally, we congratulate the authors for this
excellent and well-defined study and for their contribution to the
optimization of the clinical outcomes in patients undergoing
CABG after myocardial revascularization.
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Reply
We read with interest the letters by Drs. Kulik and Ruel and by
Dr. Bisdas and colleagues commenting on our study about the
efficacy of clopidogrel treatment in patients with myocardial
infarction (MI) treated with coronary artery bypass graft surgery
(CABG) (1).
Our study was a nationwide cohort study based on exact
information from nationwide registers of claimed prescriptions and
hospitalizations in Denmark. Although these registers include
comprehensive data, some details are not listed, for example,
on-pump/off-pump, whereas platelet function tests are currently
not recommended for routine use (2). Including these variables
might have increased the accuracy of our models, but we do not
believe it would have changed the results substantially. Impor-
tantly, we found reduced mortality among patients receiving
clopidogrel after CABG. This finding was consistent in the
propensity-matched subgroup analysis. We did not find reduced
recurrent MIs. However, contrary to the statement by Drs. Kulik
and Ruel, we found reduced cardiovascular death among the
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August 30, 2011:1081–6patients receiving clopidogrel (1). This difference persisted across
the propensity-matched subgroups, but was nonsignificant (p 
0.19) due to the low number of patients. A discussion of this
was presented in the paper (1). In our study, all patients had
severe ischemic heart disease, and the lack of effect on recurrent
MI might be explained by the fact that a recurrent event in
these patients often is fatal, a statement supported by data from
the CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of
Ischemic Events) (3) and PLATO (Platelet Inhibition and
Patient Outcomes) (4) trials. We stated that clopidogrel was
underused because only 27% received clopidogrel after CABG,
even though guidelines clearly recommend 9 to 12 months of
treatment. We acknowledge that the evidence behind this
recommendation is weak (5), which was one reason we per-
formed our study. We also recognize the effort of providing data
on graft patency in the CASCADE (Clopidogrel After Surgery
for Coronary Artery DiseasE) trial, but we are not confident of
the conclusions due to the low number of patients (6). Further-
more, graft patency is a surrogate endpoint that does not
necessarily reflect clinical events. Finally, the favorable effect of
clopidogrel in our study may indicate that clopidogrel resistance
is less important in this clinical setting. In summary, an
adequately powered randomized trial is needed to clarify the
efficacy and safety of clopidogrel treatment in MI patients
undergoing CABG. Until then, we recommend following
current guidelines and continue clopidogrel 9 to 12 months
after MI.
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